EQT to buy molecular testing firm Qiagen for $10.8 billion

EQT will acquire Qiagen for €9.6B ($10.78B), offering €46.50 ($52.22) per share, an 8.6% premium. Qiagen's shares rose 0.7% post-announcement. The deal, valued at $12.1B including debt, is expected to close in mid-2027. Qiagen's board approved the offer, citing it as the best path forward. The company suspended its 2026 outlook and reported Q3 net sales of $548M and adjusted EPS of $0.65.

Original reporting
Published Oct 21, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
EQT to buy molecular testing firm Qiagen for $10.8 billion — source image
Decision brief

The 30-second read

$QGENBullishHigh
01

Why it matters

The announcement provides a clear catalyst for Qiagen's stock, with a modest immediate price uptick and likely continued upside as the deal progresses toward a mid‑2027 close.

02

Market read

First‑report of a major M&A transaction that directly moves a US‑listed biotech stock, offering a concrete trading opportunity.

03

What to watch

Potential integration risks and the impact of Qiagen's pending full‑year outlook suspension on future earnings.

Relevance 9/10Novelty 9/10Timing: after‑hours reaction

Background

EQT, a Sweden‑based private‑equity firm, is expanding its portfolio in molecular diagnostics by targeting Qiagen, a Dutch‑origin company listed in the US. The offer follows prior interest from other PE firms and a failed 2020 acquisition attempt by Thermo Fisher.

Company-level read

Ticker impact

$QGENBullishHigh confidence
Context

Qiagen announced a definitive €9.6 billion buyout by EQT, offering €46.50 per share, a premium that caused its US‑listed shares to rise 0.7% in extended trading.

Expected impact

modest upside as the market incorporates the 8.6% premium and buy‑out certainty

Evidence & confidence

Deal is newly disclosed, large scale, and already moved the share price; no competing bids are mentioned.

Market effects

The deal underscores private‑equity appetite for molecular‑testing firms, potentially prompting valuation reassessments in the biotech diagnostics sector.

European private‑equity activity may see heightened interest, but direct impact is limited to US‑listed Qiagen.

Large‑cap M&A of this size can influence global biotech M&A sentiment and comparable deal multiples.

Counterpoint

If the deal faces regulatory hurdles or financing delays, the premium could evaporate, leaving the stock vulnerable to a pull‑back.

Key entities

  • EQT

    Acquirer offering €46.50 per share.

  • Qiagen

    Target of the €9.6 billion buyout, ticker QGEN.

Related articles

$QGENMed

Bank of America Reports 5.50% QIAGEN Stake

Bank of America reported a 5.50% stake in QIAGEN, including 2.26% indirect real and 3.24% indirect potential interests, according to a November 5, 2026, notification by the Netherlands AFM. QIAGEN noted it is not responsible for the accuracy of the notification.

$QGENMed

QIAGEN N.V. (QGEN): Financial results for Q3 2026

QIAGEN N.V. (QGEN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Media Release QIAGEN reports full Q3 2026 results • Q3 2026 results: ◦ Net sales of $548 million rise 3% and also 3% at constant exchange rates (CER) ◦ Adjusted operating income margin of 30.4% rises 0.8 percentage points ◦ Diluted EPS of $0.51; adjusted diluted EPS